Answers are grounded in this paper and cite their sources.
Our results support the notion that sWGS is an inexpensive and useful tool for the genomic analysis of ctDNA in patients with HGS-EOC to monitor disease evolution and to anticipate relapse better than serum CA-125, the routinely used clinical biomarker.See related commentary by Dhani, p. 2372.
No takes yet. Share an insight, caveat, or question.
Paracchini et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: